Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Daclizumab para la esclerosis múltiple recurrente remitente

Information

DOI:
https://doi.org/10.1002/14651858.CD008127.pub4Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 23 December 2013see what's new
Type:
  1. Intervention
Stage:
  1. Review
Cochrane Editorial Group:
  1. Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group

Copyright:
  1. Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Jia Liu

    Correspondence to: Department of Geriatric Neurology, Chinese PLA General Hospital, Beijing, China

    [email protected]

  • Lu‐Ning Wang

    Department of Geriatric Neurology, Chinese PLA General Hospital, Beijing, China

  • Siyan Zhan

    Centre for Evidence Based Medicine and Clinical Research, School of Public Health, Peking University, Beijing, China

  • Yinyin Xia

    Dept. of Surveillance and Statistics, National Center for TB Control and Prevention, China CDC, Beijing, China

Contributions of authors

Liu J and Wang L formulated the idea and developed the basis for the review.

Zhan S and Xia Y supervised the methodology and statistics.

Liu J and Wang L were in charge of updating the review.

Sources of support

Internal sources

  • Department of Geriatric Neurology, Chinese PLA General Hospital, China.

External sources

  • No sources of support supplied

Declarations of interest

None known.

Acknowledgements

The authors would like to acknowledge the help provided by Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group.

Version history

Published

Title

Stage

Authors

Version

2013 Dec 23

Daclizumab for relapsing remitting multiple sclerosis

Review

Jia Liu, Lu‐Ning Wang, Siyan Zhan, Yinyin Xia

https://doi.org/10.1002/14651858.CD008127.pub4

2012 Apr 18

Daclizumab for relapsing remitting multiple sclerosis

Review

Jia Liu, Luning Wang, Si‐Yan Zhan, Yinyin Xia

https://doi.org/10.1002/14651858.CD008127.pub3

2010 Jun 16

Daclizumab for relapsing remitting multiple sclerosis

Review

Jia Liu, Luning Wang, Siyan Zhan, Jiping Tan, Yinyin Xia

https://doi.org/10.1002/14651858.CD008127.pub2

2009 Oct 07

Daclizumab for relapsing remitting multiple sclerosis

Protocol

Jia Liu, Luning Wang, Siyan Zhan, Jiping Tan, Yinyin Xia

https://doi.org/10.1002/14651858.CD008127

Differences between protocol and review

None.

Keywords

MeSH

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.

Study flow diagram.
Figures and Tables -
Figure 1

Study flow diagram.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figures and Tables -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figures and Tables -
Figure 3

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Comparison 1 Safety, Outcome 1 Any adverse event.
Figures and Tables -
Analysis 1.1

Comparison 1 Safety, Outcome 1 Any adverse event.

Comparison 1 Safety, Outcome 2 Serious adverse event.
Figures and Tables -
Analysis 1.2

Comparison 1 Safety, Outcome 2 Serious adverse event.

Comparison 1. Safety

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Any adverse event Show forest plot

2

851

Risk Ratio (M‐H, Random, 95% CI)

0.98 [0.89, 1.07]

2 Serious adverse event Show forest plot

2

851

Risk Ratio (M‐H, Random, 95% CI)

1.15 [0.29, 4.54]

Figures and Tables -
Comparison 1. Safety